{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:12:39Z","timestamp":1788588759941,"version":"build-2803163510"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":109,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Alzinova AB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-02082-9","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:38:04Z","timestamp":1779183484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer\u2019s disease: randomised, controlled trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Zs\u00f3fia","family":"Lovr\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Sandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Pierrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Parkkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niclas","family":"Sj\u00f6gren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Scheinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha O.","family":"Rinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2082_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A, Norton N, Fast T, Fr\u00f6lich L, Georges J, Holzapfel D, Kirabali T, Krolak-Salmon P, Rossini PM, Ferretti MT, Lanman L, Chadha AS, van der Flier WM. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement. 2023;19:658\u201370.","journal-title":"Alzheimers Dement"},{"key":"2082_CR2","doi-asserted-by":"publisher","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2082_CR3","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche MA, Hyman BT. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat Neurosci. 2020;23:1183\u201393.","journal-title":"Nat Neurosci"},{"key":"2082_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","volume":"3","author":"M Shulman","year":"2023","unstructured":"Shulman M, Kong J, O\u2019Gorman J, Ratti E, Rajagovindan R, Viollet L, Huang E, Sharma S, Racine AM, Czerkowicz J, Graham D, Li Y, Hering H, Haeberlein SB. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease. Nat Aging. 2023;3:1591\u2013601.","journal-title":"Nat Aging"},{"key":"2082_CR5","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/brain\/awad024","volume":"146","author":"H Florian","year":"2023","unstructured":"Florian H, Wang D, Arnold SE, Boada M, Guo Q, Jin Z, Zheng H, Fisseha N, Kalluri HV, Rendenbach-Mueller B, Budur K, Gold M. Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study. Brain. 2023;146:2275\u201384.","journal-title":"Brain"},{"key":"2082_CR6","doi-asserted-by":"publisher","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","volume":"101","author":"C Monteiro","year":"2023","unstructured":"Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, Sanabria Bohorquez SM, Anania VG, Wildsmith KR, Schauer SP, Lee J, Dolton MJ, Ramakrishnan V, Abramzon D, Teng E. Lauriet investigators. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet. Neurology. 2023;101:e1391\u2013401.","journal-title":"Neurology"},{"key":"2082_CR7","doi-asserted-by":"publisher","first-page":"e208061","DOI":"10.1212\/WNL.0000000000208061","volume":"102","author":"AS Fleisher","year":"2024","unstructured":"Fleisher AS, Munsie LM, Perahia DGS, Andersen SW, Higgins IA, Hauck PM, Lo AC, Sims JR, Brys M, Mintun M, PERISCOPE-ALZ Site Investigators. Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease. Neurology. 2024;102:e208061.","journal-title":"Neurology"},{"key":"2082_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","volume":"1","author":"P Novak","year":"2021","unstructured":"Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, Ropele S, Fialova L, Kramberger M, Paulenka-Ivanovova N, Smisek M, Hanes J, Stevens E, Kovac A, Sutovsky S, Parrak V, Koson P, Prcina M, Galba J, Cente M, Hromadka T, Filipcik P, Piestansky J, Samcova M, Prenn-Gologranc C, Sivak R, Froelich L, Fresser M, Rakusa M, Harrison J, Hort J, Otto M, Tosun D, Ondrus M, Winblad B, Novak M, Zilka N. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease. Nat Aging. 2021;1:521\u201334.","journal-title":"Nat Aging"},{"issue":"1","key":"2082_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13195-024-01620-7","volume":"16","author":"B Kovacech","year":"2024","unstructured":"Kovacech B, Cullen NC, Novak P, Hanes J, Kontsekova E, Katina S, Parrak V, Fresser M, Vanbrabant J, Feldman HH, Winblad B, Stoops E, Vanmechelen E, Zilka N. Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer\u2019s disease, positive for plasma p-tau217. Alzheimers Res Ther. 2024;16(1):254.","journal-title":"Alzheimers Res Ther"},{"key":"2082_CR10","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","volume":"80","author":"AL Edwards","year":"2023","unstructured":"Edwards AL, Collins JA, Junge C, Kordasiewicz H, Mignon L, Wu S, Li Y, Lin L, DuBois J, Hutchison RM, Ziogas N, Shulman M, Martarello L, Graham D, Lane R, Budd Haeberlein S, Beaver J. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2023;80:1344\u201352.","journal-title":"JAMA Neurol"},{"key":"2082_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s43587-025-01031-9","volume":"6","author":"M Shulman","year":"2026","unstructured":"Shulman M, Wu S, Ziogas N, Edwards A, Collins J, Lin L, Tien I, Curiale G, Li Y, Mummery C, Lane R, Junge C, Beaver J, Tian Y, Landen J, Bullain S, Gallagher D. Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer\u2019s disease. Nat Aging. 2026;6:445\u201353.","journal-title":"Nat Aging"},{"key":"2082_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"2082_CR13","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"2082_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"2082_CR15","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.1002\/alz.14114","volume":"20","author":"T Daly","year":"2024","unstructured":"Daly T, Kepp KP, Imbimbo BP. Are lecanemab and donanemab disease-modifying therapies? Alzheimers Dement. 2024;20:6659\u201361.","journal-title":"Alzheimers Dement"},{"key":"2082_CR16","doi-asserted-by":"publisher","first-page":"ENEURO0319","DOI":"10.1523\/ENEURO.0319-23.2024","volume":"11","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Kepp KP, Herrup K. Lecanemab and Donanemab as Therapies for Alzheimer\u2019s Disease: An Illustrated Perspective on the Data. eNeuro. 2024;11:ENEURO0319\u2013232024.","journal-title":"eNeuro"},{"key":"2082_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S2215-0366(21)00197-8","volume":"8","author":"KY Liu","year":"2021","unstructured":"Liu KY, Schneider LS, Howard R. The need to show minimum clinically important differences in Alzheimer\u2019s disease trials. Lancet Psychiatry. 2021;8:1013\u20136.","journal-title":"Lancet Psychiatry"},{"key":"2082_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, Castrillo-Viguera C, Rubino I, Vijverberg E. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer\u2019s Disease Treated with Anti-Amyloid Beta Therapy. J Prev Alzheimers Dis. 2022;9:211\u201320.","journal-title":"J Prev Alzheimers Dis"},{"key":"2082_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamaneurol.2024.3937","volume":"82","author":"S Salloway","year":"2025","unstructured":"Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R. Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025;82:19\u201329.","journal-title":"JAMA Neurol"},{"key":"2082_CR20","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.3390\/ijms21124477","volume":"21","author":"YR Huang","year":"2020","unstructured":"Huang YR, Liu RT. The Toxicity and Polymorphism of \u03b2-Amyloid Oligomers. Int J Mol Sci. 2020;21:4477.","journal-title":"Int J Mol Sci"},{"key":"2082_CR21","doi-asserted-by":"publisher","first-page":"e70519","DOI":"10.1002\/pro.70519","volume":"35","author":"MI Ivanova","year":"2026","unstructured":"Ivanova MI, La Rosa C, Ramamoorthy A. Toxic mechanisms of amyloid oligomers and therapeutic strategies. Protein Sci. 2026;35:e70519.","journal-title":"Protein Sci"},{"key":"2082_CR22","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1073\/pnas.1017033108","volume":"108","author":"M Jin","year":"2011","unstructured":"Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108:5819\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2082_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1126\/science.aay0198","volume":"365","author":"B Zott","year":"2019","unstructured":"Zott B, Simon MM, Hong W, Unger F, Chen-Engerer HJ, Frosch MP, Sakmann B, Walsh DM, Konnerth A. A vicious cycle of \u03b2 amyloid-dependent neuronal hyperactivation. Science. 2019;365:559\u201365.","journal-title":"Science"},{"key":"2082_CR24","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1523\/JNEUROSCI.5161-07.2008","volume":"28","author":"I Klyubin","year":"2008","unstructured":"Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci. 2008;28:4231\u20137.","journal-title":"J Neurosci"},{"key":"2082_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837\u201342.","journal-title":"Nat Med"},{"key":"2082_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1523\/JNEUROSCI.1698-16.2016","volume":"37","author":"T Yang","year":"2017","unstructured":"Yang T, Li S, Xu H, Walsh DM, Selkoe DJ. Large Soluble Oligomers of Amyloid \u03b2-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. J Neurosci. 2017;37:152\u201363.","journal-title":"J Neurosci"},{"key":"2082_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00401-018-1846-7","volume":"136","author":"W Hong","year":"2018","unstructured":"Hong W, Wang Z, Liu W, O\u2019Malley TT, Jin M, Willem M, Haass C, Frosch MP, Walsh DM. Diffusible, highly bioactive oligomers represent a critical minority of soluble A\u03b2 in Alzheimer\u2019s disease brain. Acta Neuropathol. 2018;136:19\u201340.","journal-title":"Acta Neuropathol"},{"key":"2082_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13195-022-01141-1","volume":"14","author":"A Sandberg","year":"2022","unstructured":"Sandberg A, Berenjeno-Correa E, Rodriguez RC, Axenhus M, Weiss SS, Batenburg K, Hoozemans JJM, Tjernberg LO, Scheper W. A\u03b242 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer\u2019s disease brain extracts. Alzheimers Res Ther. 2022;14:196.","journal-title":"Alzheimers Res Ther"},{"key":"2082_CR29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","volume":"103","author":"H Englund","year":"2007","unstructured":"Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103:334\u201345.","journal-title":"J Neurochem"},{"key":"2082_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O\u2019Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"2082_CR31","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","volume":"34","author":"MJ Savage","year":"2014","unstructured":"Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, Maxwell JW, Hatcher NG, Haugabook SJ, Wu G, Howell BJ, Renger JJ, Shughrue PJ, McCampbell A. A sensitive a\u03b2 oligomer assay discriminates Alzheimer\u2019s and aged control cerebrospinal fluid. J Neurosci. 2014;34:2884\u201397.","journal-title":"J Neurosci"},{"key":"2082_CR32","doi-asserted-by":"publisher","first-page":"7115","DOI":"10.1073\/pnas.0408582102","volume":"102","author":"AD Williams","year":"2005","unstructured":"Williams AD, Sega M, Chen M, Kheterpal I, Geva M, Berthelier V, Kaleta DT, Cook KD, Wetzel R. Structural properties of Abeta protofibrils stabilized by a small molecule. Proc Natl Acad Sci U S A. 2005;102:7115\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2082_CR33","doi-asserted-by":"publisher","first-page":"5840","DOI":"10.1074\/jbc.RA118.006559","volume":"294","author":"DF Au","year":"2019","unstructured":"Au DF, Ostrovsky D, Fu R, Vugmeyster L. Solid-state NMR reveals a comprehensive view of the dynamics of the flexible, disordered N-terminal domain of amyloid-\u03b2 fibrils. J Biol Chem. 2019;294:5840\u201353.","journal-title":"J Biol Chem"},{"key":"2082_CR34","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40265-025-02250-5","volume":"85","author":"S Abushakra","year":"2025","unstructured":"Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada Rovira M, Doraiswamy PM, Liang E, Flint S, Kesslak JP, McLaine R, Albayrak A, Schaefer J, Yu J, Tolar L, Dickson S, Hey JA, Tolar M. Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOE\u03b54\/\u03b54 Homozygotes with Early Alzheimer\u2019s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial. Drugs. 2025;85:1455\u201372.","journal-title":"Drugs"},{"key":"2082_CR35","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553\u201362.","journal-title":"Neurology"},{"key":"2082_CR36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000113700","volume":"5","author":"M Pride","year":"2008","unstructured":"Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. Progress in the active immunotherapeutic approach to Alzheimer\u2019s disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis. 2008;5:194\u20136.","journal-title":"Neurodegener Dis"},{"key":"2082_CR37","unstructured":"Triplett O, Varda N, Decourt B, Vasconcellos R, Sabbagh MN. Active Immunization Targeting Amyloid \u03b2 for the Treatment of Alzheimer\u2019s Disease. Neurodegener Dis. 2025;25(4):202\u201317. doi: 10.1159\/000546287. Epub 2025 May 10. Erratum in: Neurodegener Dis. 2025;25:228."},{"key":"2082_CR38","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ana.20592","volume":"58","author":"M Lee","year":"2005","unstructured":"Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P. Abeta42 immunization in Alzheimer\u2019s disease generates Abeta N-terminal antibodies. Ann Neurol. 2005;58:430\u20135.","journal-title":"Ann Neurol"},{"key":"2082_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1423-0127-20-10","volume":"20","author":"I Dalgediene","year":"2013","unstructured":"Dalgediene I, Lasickiene R, Budvytyte R, Valincius G, Morkuniene R, Borutaite V, Zvirbliene A. Immunogenic properties of amyloid beta oligomers. J Biomed Sci. 2013;20:10.","journal-title":"J Biomed Sci"},{"key":"2082_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13195-015-0108-3","volume":"7","author":"MR Farlow","year":"2015","unstructured":"Farlow MR, Andreasen N, Riviere ME, Vostiar I, Vitaliti A, Sovago J, Caputo A, Winblad B, Graf A. Long-term treatment with active A\u03b2 immunotherapy with CAD106 in mild Alzheimer\u2019s disease. Alzheimers Res Ther. 2015;7:23.","journal-title":"Alzheimers Res Ther"},{"key":"2082_CR41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2174\/1567205014666170117101537","volume":"14","author":"M Hull","year":"2017","unstructured":"Hull M, Sadowsky C, Arai H, Le Prince Leterme G, Holstein A, Booth K, Peng Y, Yoshiyama T, Suzuki H, Ketter N, Liu E, Ryan JM. Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer\u2019s Disease. Curr Alzheimer Res. 2017;14:696\u2013708.","journal-title":"Curr Alzheimer Res"},{"key":"2082_CR42","doi-asserted-by":"publisher","first-page":"104665","DOI":"10.1016\/j.ebiom.2023.104665","volume":"94","author":"HJ Yu","year":"2023","unstructured":"Yu HJ, Dickson SP, Wang PN, Chiu MJ, Huang CC, Chang CC, Liu H, Hendrix SB, Dodart JC, Verma A, Wang CY, Cummings J. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 2a study. EBioMedicine. 2023;94:104665.","journal-title":"EBioMedicine"},{"key":"2082_CR43","doi-asserted-by":"publisher","first-page":"15595","DOI":"10.1073\/pnas.1001740107","volume":"107","author":"A Sandberg","year":"2010","unstructured":"Sandberg A, Luheshi LM, S\u00f6llvander S, Pereira de Barros T, Macao B, Knowles TP, Biverst\u00e5l H, Lendel C, Ekholm-Petterson F, Dubnovitsky A, Lannfelt L, Dobson CM, H\u00e4rd T. Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. Proc Natl Acad Sci U S A. 2010;107:15595\u2013600.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2082_CR44","doi-asserted-by":"crossref","unstructured":"Dubnovitsky A, Sandberg A, Rahman MM, Benilova I, Lendel C, H\u00e4rd T. Amyloid-\u03b2 protofibrils: size, morphology and synaptotoxicity of an engineered mimic. PLoS ONE. 2013;8:e66101.","DOI":"10.1371\/journal.pone.0066101"},{"key":"2082_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI200318104","volume":"112","author":"A Monsonego","year":"2003","unstructured":"Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest. 2003;112:415\u201322.","journal-title":"J Clin Invest"},{"key":"2082_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"2082_CR47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367\u201385.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"2082_CR48","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412\u20134.","journal-title":"Neurology"},{"key":"2082_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"2082_CR50","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266\u201377.","journal-title":"Am J Psychiatry"},{"issue":"Suppl 2","key":"2082_CR51","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","volume":"11","author":"LS Schneider","year":"1997","unstructured":"Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH. Validity and reliability of the Alzheimer\u2019s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer\u2019s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S22\u201332.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2082_CR52","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","volume":"87","author":"J Wang","year":"2016","unstructured":"Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, Dhadda S, Do I, Rabe M, Luthman J, Cummings J, Satlin A. ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s disease trials. J Neurol Neurosurg Psychiatry. 2016;87:993\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2082_CR53","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566\u201372.","journal-title":"Br J Psychiatry"},{"key":"2082_CR54","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JAD-170991","volume":"63","author":"JK Kueper","year":"2018","unstructured":"Kueper JK, Speechley M, Montero-Odasso M. The Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review. J Alzheimers Dis. 2018;63:423\u201344.","journal-title":"J Alzheimers Dis"},{"key":"2082_CR55","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1001\/archneur.64.9.1323","volume":"64","author":"J Harrison","year":"2007","unstructured":"Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007;64:1323\u20139.","journal-title":"Arch Neurol"},{"issue":"Suppl 2","key":"2082_CR56","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","volume":"11","author":"D Galasko","year":"1997","unstructured":"Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease. The Alzheimer\u2019s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33\u20139.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2082_CR57","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308\u201314.","journal-title":"Neurology"},{"key":"2082_CR58","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-018-0339-1","volume":"10","author":"L Gaetani","year":"2018","unstructured":"Gaetani L, H\u00f6glund K, Parnetti L, Pujol-Calderon F, Becker B, Eusebi P, Sarchielli P, Calabresi P, Di Filippo M, Zetterberg H, Blennow K. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther. 2018;10:8.","journal-title":"Alzheimers Res Ther"},{"key":"2082_CR59","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","volume":"7","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, Kornhuber J, Hansson O, Minthon L, Spitzer P, Maler JM, Zetterberg H, Blennow K, Lewczuk P. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls. Alzheimers Res Ther. 2015;7:40.","journal-title":"Alzheimers Res Ther"},{"key":"2082_CR60","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1177\/1352458515624558","volume":"22","author":"A \u00d6hrfelt","year":"2016","unstructured":"\u00d6hrfelt A, Axelsson M, Malmestr\u00f6m C, Novakova L, Heslegrave A, Blennow K, Lycke J, Zetterberg H. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Mult Scler. 2016;22:1587\u201395.","journal-title":"Mult Scler"},{"key":"2082_CR61","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2021","unstructured":"Gobom J, Parnetti L, Rosa-Neto P, Vyhnalek M, Gauthier S, Cataldi S, Lerch O, Laczo J, Cechova K, Clarin M, Benet AL, Pascoal TA, Rahmouni N, Vandijck M, Huyck E, Le Bastard N, Stevenson J, Chamoun M, Alcolea D, Lle\u00f3 A, Andreasson U, Verbeek MM, Bellomo G, Rinaldi R, Ashton NJ, Zetterberg H, Sheardova K, Hort J, Blennow K. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med. 2021;60:207\u201319.","journal-title":"Clin Chem Lab Med"},{"key":"2082_CR62","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/alz.13525","volume":"20","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz F, Ferreira PCL, Gonz\u00e1lez-Escalante A, Montoliu-Gaya L, Ortiz-Romero P, Kac PR, Turton M, Kvartsberg H, Ashton NJ, Zetterberg H, Harrison P, Bellaver B, Povala G, Villemagne VL, Pascoal TA, Ganguli M, Cohen AD, Minguillon C, Contador J, Su\u00e1rez-Calvet M, Karikari TK, Blennow K. A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer\u2019s disease. Alzheimers Dement. 2024;20:1239\u201349.","journal-title":"Alzheimers Dement"},{"key":"2082_CR63","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13195-022-01021-8","volume":"14","author":"J Nilsson","year":"2022","unstructured":"Nilsson J, Ashton NJ, Benedet AL, Montoliu-Gaya L, Gobom J, Pascoal TA, Chamoun M, Portelius E, Jeromin A, Mendes M, Zetterberg H, Rosa-Neto P, Brinkmalm A, Blennow K. Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:78.","journal-title":"Alzheimers Res Ther"},{"key":"2082_CR64","doi-asserted-by":"publisher","first-page":"e12540","DOI":"10.1002\/dad2.12540","volume":"16","author":"D Evenden","year":"2024","unstructured":"Evenden D, Prosser A, Michopoulou S, Kipps C. for the Alzheimer\u2019s Disease Neuroimaging Initiative. ADCOMS sensitivity versus baseline diagnosis and progression phenotypes. Alzheimers Dement (Amst). 2024;16:e12540.","journal-title":"Alzheimers Dement (Amst)"},{"key":"2082_CR65","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40120-022-00326-y","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J. Alzheimer\u2019s Disease Neuroimaging Initiative. Staging Disease Severity Using the Alzheimer\u2019s Disease Composite Score (ADCOMS): A Retrospective Data Analysis. Neurol Ther. 2022;11:413\u201334.","journal-title":"Neurol Ther"},{"key":"2082_CR66","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jrp.2013.05.009","volume":"47","author":"FD Sch\u00f6nbrodt","year":"2013","unstructured":"Sch\u00f6nbrodt FD, Perugini M. At what sample size do correlations stabilize? J Res Pers. 2013;47:609\u201312.","journal-title":"J Res Pers"},{"key":"2082_CR67","doi-asserted-by":"publisher","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","volume":"100","author":"F Alves","year":"2023","unstructured":"Alves F, Kalinowski P, Ayton S. Accelerated Brain Volume Loss Caused by Anti-\u03b2-Amyloid Drugs: A Systematic Review and Meta-analysis. Neurology. 2023;100:e2114\u201324.","journal-title":"Neurology"},{"key":"2082_CR68","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3988\/jcn.2025.0324","volume":"22","author":"SJ Yang","year":"2026","unstructured":"Yang SJ, Lim JS, Choi Y, Kim HS, Kim SJ, Lee JH, Suh CH. Comparing Susceptibility-Weighted Imaging and T2* Gradient-Recalled Echo for Cerebral Microbleeds Detection: A Systematic Review and Meta-Analysis. J Clin Neurol. 2026;22:193\u2013202.","journal-title":"J Clin Neurol"},{"key":"2082_CR69","doi-asserted-by":"publisher","first-page":"100220","DOI":"10.1016\/j.tjpad.2025.100220","volume":"12","author":"DM Sima","year":"2025","unstructured":"Sima DM, Phan TV, Franceschi AM, Gibbs WN, Barkhof F, Scheltens P, Salloway S, Cummings J, Van Hecke W, Smeets D. Monitoring of amyloid related imaging abnormalities: SWI vs T2*-GRE. J Prev Alzheimers Dis. 2025;12:100220.","journal-title":"J Prev Alzheimers Dis"},{"key":"2082_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3174\/ajnr.A8469","volume":"46","author":"PM Cogswell","year":"2025","unstructured":"Cogswell PM, Andrews TJ, Barakos JA, Barkhof F, Bash S, Benayoun MD, Chiang GC, Franceschi AM, Jack CR Jr, Pillai JJ, Poussaint TY, Raji CA, Ramanan VK, Tanabe J, Tanenbaum L, Whitlow CT, Yu FF, Zaharchuk G, Zeinah M, Benzinger TS. ASNR Alzheimer, ARIA, and Dementia Study Group. Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities. AJNR Am J Neuroradiol. 2025;46:24\u201332.","journal-title":"AJNR Am J Neuroradiol"},{"key":"2082_CR71","doi-asserted-by":"crossref","unstructured":"Yates PA, Villemagne VL, Ellis KA, Desmond PM, Masters CL, Rowe CC. Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Front Neurol., van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P. Prevalence and severity of microbleeds in a memory clinic setting. Neurology. 2006;66:1356-60.","DOI":"10.1212\/01.wnl.0000210535.20297.ae"},{"key":"2082_CR72","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1212\/01.wnl.0000210535.20297.ae","volume":"66","author":"C Cordonnier","year":"2006","unstructured":"Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P. Prevalence and severity of microbleeds in a memory clinic setting. Neurology. 2006;66:1356\u201360.","journal-title":"Neurology"},{"key":"2082_CR73","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1212\/WNL.0b013e3181e396ea","volume":"74","author":"JD Goos","year":"2010","unstructured":"Goos JD, Henneman WJ, Sluimer JD, Vrenken H, Sluimer IC, Barkhof F, Blankenstein MA, Scheltens PH, van der Flier WM. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology. 2010;74:1954\u201360.","journal-title":"Neurology"},{"key":"2082_CR74","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1007\/s00415-003-0245-7","volume":"250","author":"H Hanyu","year":"2003","unstructured":"Hanyu H, Tanaka Y, Shimizu S, Takasaki M, Abe K. Cerebral microbleeds in Alzheimer\u2019s disease. J Neurol. 2003;250:1496\u20137.","journal-title":"J Neurol"},{"key":"2082_CR75","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/archneur.65.6.790","volume":"65","author":"JA Pettersen","year":"2008","unstructured":"Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK, St George-Hyslop P, Rogaeva E, Black SE. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol. 2008;65:790\u20135.","journal-title":"Arch Neurol"},{"key":"2082_CR76","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3233\/JAD-2009-1073","volume":"17","author":"W Kirsch","year":"2009","unstructured":"Kirsch W, McAuley G, Holshouser B, Petersen F, Ayaz M, Vinters HV, Dickson C, Haacke EM, Britt W 3rd, Larseng J, Kim I, Mueller C, Schrag M, Kido D. Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia. J Alzheimers Dis. 2009;17:599\u2013609.","journal-title":"J Alzheimers Dis"},{"key":"2082_CR77","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Donanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"2082_CR78","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS. GRADUATE I and II Investigators and the Gantenerumab Study Group. Two Phase 3 Trials of Gantenerumab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;389:1862\u201376.","journal-title":"N Engl J Med"},{"key":"2082_CR79","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jneuroim.2014.06.017","volume":"274","author":"BX Qu","year":"2014","unstructured":"Qu BX, Gong Y, Moore C, Fu M, German DC, Chang LY, Rosenberg R, Diaz-Arrastia R. Beta-amyloid auto-antibodies are reduced in Alzheimer\u2019s disease. J Neuroimmunol. 2014;274:168\u201373.","journal-title":"J Neuroimmunol"},{"key":"2082_CR80","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.2741\/3496","volume":"14","author":"JH Sohn","year":"2009","unstructured":"Sohn JH, So JO, Hong HJ, Kim JW, Na DR, Kim M, Kim H, Nam E, Ha HJ, Kim YH, Mook-Jung I. Identification of autoantibody against beta-amyloid peptide in the serum of elderly. Front Biosci (Landmark Ed). 2009;14:3879\u201383.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2082_CR81","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0531-5565(02)00029-3","volume":"37","author":"ME Weksler","year":"2002","unstructured":"Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37:943\u20138.","journal-title":"Exp Gerontol"},{"key":"2082_CR82","doi-asserted-by":"publisher","first-page":"12145","DOI":"10.1073\/pnas.0904866106","volume":"106","author":"M Britschgi","year":"2009","unstructured":"Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2009;106:12145\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2082_CR83","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1742-2094-8-93","volume":"8","author":"AC Klaver","year":"2011","unstructured":"Klaver AC, Coffey MP, Smith LM, Bennett DA, Finke JM, Dang L, Loeffler DA. ELISA measurement of specific non-antigen-bound antibodies to A\u03b21\u201342 monomer and soluble oligomers in sera from Alzheimer\u2019s disease, mild cognitively impaired, and noncognitively impaired subjects. J Neuroinflammation. 2011;8:93.","journal-title":"J Neuroinflammation"},{"key":"2082_CR84","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.brainres.2008.02.060","volume":"1219","author":"W Xu","year":"2008","unstructured":"Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y, Ikeda M, Amari M, Kuwano R, Abe K, Shoji M. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer\u2019s disease and normal controls. Brain Res. 2008;1219:169\u201379.","journal-title":"Brain Res"},{"key":"2082_CR85","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jneuroim.2007.03.023","volume":"186","author":"MA Gruden","year":"2007","unstructured":"Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, Wilhelm K, Elistratova EI, Sherstnev VV, Morozova-Roche LA. Differential neuroimmune markers to the onset of Alzheimer\u2019s disease neurodegeneration and dementia: autoantibodies to Abeta((25\u201335)) oligomers, S100b and neurotransmitters. J Neuroimmunol. 2007;186:181\u201392.","journal-title":"J Neuroimmunol"},{"key":"2082_CR86","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/j.1471-4159.2008.05477.x","volume":"106","author":"KA Gustaw","year":"2008","unstructured":"Gustaw KA, Garrett MR, Lee HG, Castellani RJ, Zagorski MG, Prakasam A, Siedlak SL, Zhu X, Perry G, Petersen RB, Friedland RP, Smith MA. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem. 2008;106:1350\u20136.","journal-title":"J Neurochem"},{"key":"2082_CR87","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.exger.2009.10.003","volume":"45","author":"KA Gustaw-Rothenberg","year":"2010","unstructured":"Gustaw-Rothenberg KA, Siedlak SL, Bonda DJ, Lerner A, Tabaton M, Perry G, Smith MA. Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer\u2019s disease: a population-based study. Exp Gerontol. 2010;45:47\u201352.","journal-title":"Exp Gerontol"},{"key":"2082_CR88","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1385\/NMM:3:1:29","volume":"3","author":"A Nath","year":"2003","unstructured":"Nath A, Hall E, Tuzova M, Dobbs M, Jons M, Anderson C, Woodward J, Guo Z, Fu W, Kryscio R, Wekstein D, Smith C, Markesbery WR, Mattson MP. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer\u2019s disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med. 2003;3:29\u201339.","journal-title":"Neuromolecular Med"},{"key":"2082_CR89","doi-asserted-by":"publisher","first-page":"eabb0457","DOI":"10.1126\/sciadv.abb0457","volume":"7","author":"YH Liu","year":"2021","unstructured":"Liu YH, Wang J, Li QX, Fowler CJ, Zeng F, Deng J, Xu ZQ, Zhou HD, Doecke JD, Villemagne VL, Lim YY, Masters CL, Wang YJ. Association of naturally occurring antibodies to \u03b2-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer\u2019s disease. Sci Adv. 2021;7:eabb0457.","journal-title":"Sci Adv"},{"key":"2082_CR90","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1084\/jem.20180199","volume":"216","author":"GT Norris","year":"2019","unstructured":"Norris GT, Kipnis J. Immune cells and CNS physiology: Microglia and beyond. J Exp Med. 2019;216:60\u201370.","journal-title":"J Exp Med"},{"key":"2082_CR91","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.immuni.2024.06.009","volume":"57","author":"JG Cyster","year":"2024","unstructured":"Cyster JG, Wilson PC. Antibody modulation of B cell responses-Incorporating positive and negative feedback. Immunity. 2024;57:1466\u201381.","journal-title":"Immunity"},{"key":"2082_CR92","doi-asserted-by":"publisher","first-page":"e2519919","DOI":"10.1001\/jamanetworkopen.2025.19919","volume":"8","author":"DM de Leeuw","year":"2025","unstructured":"de Leeuw DM, Trieu C, Vromen EM, Blujdea ER, Verberk IMW, Duits FH, Teunissen CE, Pijnenburg YAL, van der Flier WM, van Harten AC, Visser PJ, Tijms BM. Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum. JAMA Netw Open. 2025;8:e2519919.","journal-title":"JAMA Netw Open"},{"key":"2082_CR93","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3233\/JAD-221305","volume":"93","author":"RJ Castellani","year":"2023","unstructured":"Castellani RJ, Shanes ED, McCord M, Reish NJ, Flanagan ME, Mesulam MM, Jamshidi P. Neuropathology of Anti-Amyloid-\u03b2 Immunotherapy: A Case Report. J Alzheimers Dis. 2023;93:803\u201313.","journal-title":"J Alzheimers Dis"},{"key":"2082_CR94","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato C, Barth\u00e9lemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM, Kanaan NM, Yarasheski KE, Baker-Nigh A, Benzinger TLS, Miller TM, Karch CM, Bateman RJ. Tau Kinetics in Neurons and the Human Central Nervous System. Neuron. 2018;97:1284\u2013e12987.","journal-title":"Neuron"},{"key":"2082_CR95","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","volume":"79","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, Collins EC, Sims JR, Mintun MA. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. 2022;79:1250\u20139.","journal-title":"JAMA Neurol"},{"key":"2082_CR96","doi-asserted-by":"publisher","first-page":"e14414","DOI":"10.1002\/alz.14414","volume":"21","author":"T Bittner","year":"2025","unstructured":"Bittner T, Tonietto M, Klein G, Belusov A, Illiano V, Voyle N, Delmar P, Scelsi MA, Gobbi S, Silvestri E, Barakovic M, Napolitano A, Galli C, Abaei M, Blennow K, Barkhof F. Biomarker treatment effects in two phase 3 trials of gantenerumab. Alzheimers Dement. 2025;21:e14414.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02082-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:02:32Z","timestamp":1788588152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02082-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2082"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02082-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with international and national regulations governing biomedical research involving human subjects, including the Declaration of Helsinki, Good Clinical Practice, and all applicable Finnish national regulations. Prior to initiation, the study protocol and informed consent materials received approval from the National Committee on Medical Research Ethics (TUKIJA). All participants provided written informed consent before any study procedures were undertaken.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD; is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of CERimmune Therapeutics (outside submitted work).","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"198"}}